Double Blind Randomized Study, Comparing Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS
Phase of Trial: Phase III
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Rifaximin (Primary)
- Indications Hepatic encephalopathy
- Focus Therapeutic Use
- Acronyms PRPET
- 25 Oct 2017 Status changed from recruiting to completed.
- 21 Feb 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 21 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.